Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JNCE Jounce Therapeutics (JNCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Jounce Therapeutics Stock (NASDAQ:JNCE) 30 days 90 days 365 days Advanced Chart Ad StocksToTradeMy Top Trump Rally StocksThis Catalyst Hits Once Every 4 Years.. Every four years, on the day of the election, a catalyst is triggered. Over the last 20 years, this catalyst has caused 1,500 stocks to rise an average of 3,700%... within 90 days. And now, Tim Bohen is blowing the whole story wide open on Wednesday, November 20th at 8PM.Click here for details on your FREE RSVP. Get Jounce Therapeutics alerts:Sign Up Key Stats Today's Range$1.88▼$1.9350-Day Range$1.84▼$1.9452-Week Range$0.58▼$5.87Volume11.60 million shsAverage Volume2.46 million shsMarket Capitalization$98.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Read More… My Top Trump Rally Stocks (Ad)This Catalyst Hits Once Every 4 Years.. Every four years, on the day of the election, a catalyst is triggered. Over the last 20 years, this catalyst has caused 1,500 stocks to rise an average of 3,700%... within 90 days. And now, Tim Bohen is blowing the whole story wide open on Wednesday, November 20th at 8PM.Click here for details on your FREE RSVP. Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Stock News HeadlinesTaboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) PropertiesOctober 2, 2024 | markets.businessinsider.comSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusNovember 27, 2023 | bizjournals.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 15, 2024 | Colonial Metals (Ad)Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceSeptember 19, 2023 | tmcnet.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 18, 2023 | finance.yahoo.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaSeptember 5, 2023 | tmcnet.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comSee More Headlines JNCE Stock Analysis - Frequently Asked Questions How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics, Inc. (NASDAQ:JNCE) released its earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. When did Jounce Therapeutics IPO? Jounce Therapeutics (JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK). Company Calendar Last Earnings11/04/2021Today11/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:JNCE CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone(857) 259-3840FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,920,000.00 Net MarginsN/A Pretax Margin-61.93% Return on Equity-30.90% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio8.37 Quick Ratio8.37 Sales & Book Value Annual Sales$82 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book0.53Miscellaneous Outstanding Shares52,630,000Free Float48,993,000Market Cap$98.94 million OptionableOptionable Beta0.75 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:JNCE) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jounce Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
